Immune checkpoint inhibitors, FGFR3 inhibitors, and antibody drug-conjugates are recent additions to the armamentarium of agents used to treat advanced urothelial cancer (UC). However, cisplatin-based therapy remains a standard front-line treatment for eligible patients with metastatic UC. Angiogenesis is a critical pathway in UC development and progression. Early-phase clinical trials suggested that targeting angiogenesis could potentially improve outcomes in advanced UC. However, sufficiently powered randomized controlled trials testing the efficacy of antiangiogenic agents were lacking.

X